Biogen’s Q1 revenue soars past estimates as rare disease pivot pays off

May 2, 2025 - 06:00

Biogen’s Q1 revenue soars past estimates as rare disease pivot pays off

Read the original article

Tags:

Previous Article

Repare signs out-licensing deal with DCx Biotherapeutics

Lilly’s Q1 2025 revenue jumps 45%, but CVS shift boosts Novo’s Wegovy

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Gilead acquires CymaBay Therapeutics for $4.3bn

Gilead acquires CymaBay Therapeutics for $4.3bn

Mar 26, 2024

STAT+: DarioHealth acquires Twill, hoping it’s a shortcut to profitability

STAT+: DarioHealth acquires Twill, hoping it’s a shortc...

Feb 21, 2024

D3L-001 by D3 Bio for Human Epidermal Growth Factor Rec...

Nov 4, 2023